Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-05-30
2006-05-30
Brumback, Brenda (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S192100, C514S002600, C514S012200, C530S350000, C530S387300, C536S023400
Reexamination Certificate
active
07052691
ABSTRACT:
Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as a VEGF trap capable of binding and blocking VEGF.
REFERENCES:
patent: 6524583 (2003-02-01), Thorpe et al.
patent: 2003/0017977 (2003-01-01), Xia et al.
patent: WO 02/060489 (2000-08-01), None
patent: WO 00/75319 (2000-12-01), None
Pettit et al. (1998). The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals. Trends Biotechnol 16: 343-349.
De Vriese, A., et al., 2001, “Antibodies Against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experiment Diabetes”, J. Am. Soc. Nephrol. 12:993-1000.
Ereemina, V., et al., 2003, “Glomerular-Specific Alterations of VEGF-A Expression Lead to Distinct Congenital and Acquired Renal Diseases”, J. Clin. Invest. 111:707-716.
Cooper, M., et al., 1999, “Increased Renal Expression of Vascular Endothelial Growth Factor (VEGF) and Its Receptor VEGFR-2 in Experimental Diabetes”, Diabetes, 48:2229-2239.
Flyvbjerg, A., et al., 2002, “Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody”, Diabetes, 51:3090-3094.
Holash, J., et al., (2002) PNAS, 99(17):11393-11398.
Heidaran, M.A., et al., (1990) J. Biol. Chem. 265(31):18741-18744.
Cunningham, S.A., et al., (1997) Biochem. Biophys. Res. Comm. 231;596-599.
Fuh, G., et al., (1998) J. Biol. Chem. 273(18):11197-11204.
Wiesmann, C., et al., (1997) Cell, 91:695-704.
Barleon, B., et al., (1997) J. Biol. Chem. 272(16):10382-10388.
Davis-Smyth, T., et al., (1998) J. Biol. Chem. 273(6):3216-3222.
Sleeman Mark W.
Wiegand Stanley J.
Brumback Brenda
Gregg, Esq. Valeta
Lockard Jon M
Regeneron Pharmaceuticals Inc.
LandOfFree
Methods of treating diabetes by blocking VEGF-mediated activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating diabetes by blocking VEGF-mediated activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating diabetes by blocking VEGF-mediated activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3573125